PropertyValue
?:abstract
  • INTRODUCTION: The world is currently fighting a COVID-19 pandemic, perhaps the most disruptive infectious disease outbreak since the 1918 Spanish influenza. Governments have taken drastic measures to curb the spread of SARS-CoV-2, and the development of safe and efficacious vaccine candidates is being accelerated. The possibility of vaccine-mediated disease enhancement with coronavirus vaccines has been flagged as a potential safety concern, and, despite the urgent need, should be thoroughly assessed as vaccines against SARS-CoV-2 are being tested. AREA COVERED: We review the in vivo evidence suggesting a theoretical risk of disease enhancement after vaccination with SARS-CoV and MERS-CoV vaccine candidates. We also identify knowledge gaps that need to be filled to maximize the chance of developing a safe vaccine and minimize the risk of encountering disease enhancement in vaccinated individuals after exposure to SARS-CoV-2. EXPERT OPINION: We compile and propose avenues to investigate the risk of vaccine-mediated disease enhancement both during pre-clinical and early clinical development. While the pressing need for a vaccine against COVID-19 (and future epidemic coronaviruses) cannot be ignored, we advocate to keep safety at the center of the debate. Protecting individuals with effective and safe vaccines should be a priority, even during extraordinary times like the COVID-19 pandemic.
?:creator
?:doi
?:doi
  • 10.1080/14760584.2020.1800463
?:journal
  • Expert_review_of_vaccines
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/7a9538c54d7b0a845795a992efa92ffe44bbe03c.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7566857.xml.json
?:pmcid
?:pmid
?:pmid
  • 32838605.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns
?:type
?:year
  • 2020-08-24

Metadata

Anon_0  
expand all